(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
PubChem CID: 159594
Atrasentan is a member of the class of pyrrolidines that is pyrrolidine substituted by 2-(dibutylamino)-2-oxoethyl, 4-methoxyphenyl, carboxy, and 1,3-benzodioxol-5-yl groups at positions 1, 2, 3, and 4, respectively (the 2R,3R,4S-stereoisomer). It is an endothelin endothelin type A receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy. It has a role as an endothelin A receptor antagonist and a nephroprotective agent. It is a tertiary carboxamide, a monomethoxybenzene, a monocarboxylic acid, a member of pyrrolidines, a member of benzodioxoles, a pyrrolidinecarboxylic acid and a tertiary amino compound.
Canonical SMILES
SMILES: This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Trials and conditions connected to Atrasentan